Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

This study has been completed.
Information provided by:
Gachon University Gil Medical Center Identifier:
First received: August 20, 2008
Last updated: August 28, 2008
Last verified: August 2008
The investigators hypothesized combination therapy would be superior to monotherapy.

Condition Intervention Phase
Drug: statin, amlodipine
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Crossover Assignment
Primary Purpose: Treatment
Official Title: Additive Beneficial Effects of Atorvastatin Combined With Amlodipine In Treatment of Hypertension

Resource links provided by NLM:

Further study details as provided by Gachon University Gil Medical Center:

Study Start Date: December 2004
Study Completion Date: August 2008
Arms Assigned Interventions
Experimental: atorvastatin, amlodipine Drug: statin, amlodipine


Ages Eligible for Study:   25 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hypertension

Exclusion Criteria:

  • Chronic renal disease
  • Severe hypertension
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00741078

Korea, Republic of
Gil Medical Center
Incheon, Korea, Republic of, 405-760
Sponsors and Collaborators
Gachon University Gil Medical Center
  More Information Identifier: NCT00741078     History of Changes
Other Study ID Numbers: GMC-200504 
Study First Received: August 20, 2008
Last Updated: August 28, 2008
Health Authority: South Korea: Institutional Review Board

Keywords provided by Gachon University Gil Medical Center:

Additional relevant MeSH terms:
Cardiovascular Diseases
Vascular Diseases
Atorvastatin Calcium
Anticholesteremic Agents
Antihypertensive Agents
Calcium Channel Blockers
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents processed this record on May 22, 2016